Unternehmen wird geladen
Just reported
Q3 2026 results
From OPKO Health's results release of 4. November 2026; its quarterly report has since been filed.
Revenue
Actual
65,4M $
+16 % y/y
-60 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,07 $
Guided
—
No guide given
Operating income, GAAP
Actual
-31,4M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes OPKO Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.259,4B $A+
IDXXIdexx Laboratories Inc.55,5B $A+
IQVIQVIA Holdings Inc.43,7B $A
ILMNIllumina, Inc.31,3B $A+
LHLabcorp Holdings Inc.30,1B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Gebaut aus den eigenen Einreichungen von OPKO Health, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
